2019
PI-RADS Steering Committee: The PI-RADS Multiparametric MRI and MRI-directed Biopsy Pathway
Padhani AR, Barentsz J, Villeirs G, Rosenkrantz AB, Margolis DJ, Turkbey B, Thoeny HC, Cornud F, Haider M, Macura K, Tempany C, Verma S, Weinreb J. PI-RADS Steering Committee: The PI-RADS Multiparametric MRI and MRI-directed Biopsy Pathway. Radiology 2019, 292: 464-474. PMID: 31184561, PMCID: PMC6677282, DOI: 10.1148/radiol.2019182946.Peer-Reviewed Original ResearchConceptsBiopsy pathwayProstate cancerLife-threatening prostate cancerBiopsy-naive menNegative biopsy resultsClinical care guidelinesHigh-quality evidenceSignificant prostate cancerRoutine clinical practiceProstate Imaging ReportingGreater clinical utilityNumber of diagnosesProstate cancer detectionClinical suspicionInsignificant cancerCare guidelinesBiopsy resultsProstate biopsyTransrectal USMRI pathwayPositive health impactsNumber of menBiopsy increasesIncorporation of MRIClinical utility
2018
MRI-Ultrasound Fusion Targeted Biopsy of Prostate Imaging Reporting and Data System Version 2 Category 5 Lesions Found False-Positive at Multiparametric Prostate MRI.
Sheridan AD, Nath SK, Aneja S, Syed JS, Pahade J, Mathur M, Sprenkle P, Weinreb JC, Spektor M. MRI-Ultrasound Fusion Targeted Biopsy of Prostate Imaging Reporting and Data System Version 2 Category 5 Lesions Found False-Positive at Multiparametric Prostate MRI. American Journal Of Roentgenology 2018, 210: w218-w225. PMID: 29489409, DOI: 10.2214/ajr.17.18680.Peer-Reviewed Original ResearchConceptsPI-RADS 5 lesionsBenign pathologic resultsLower prostate-specific antigen densitySignificant prostate cancerProstate-specific antigen densityBenign prostatic hyperplasia nodulesMRI-ultrasound fusionProstate Imaging ReportingCategory 5 lesionsPathologic resultsProstate cancerClinical featuresBenign diseaseAntigen densityImaging ReportingGleason 6 diseasePI-RADS version 2High-risk lesionsMultivariate logistic regressionRoutine clinical interpretationMultiparametric prostate MRIInflammatory changesNormal anatomic structuresBiopsy resultsTargeted biopsiesIs PI-RADS 3/total lesion ratio associated with clinically-significant prostate cancer in patients with equivocal-risk lesions on multi-parametric MRI?
Ghabili K, Swallow M, Suarez-Sarmiento A, Syed J, Leapman M, Weinreb J, Sprenkle P. Is PI-RADS 3/total lesion ratio associated with clinically-significant prostate cancer in patients with equivocal-risk lesions on multi-parametric MRI? Journal Of Clinical Oncology 2018, 36: 149-149. DOI: 10.1200/jco.2018.36.6_suppl.149.Peer-Reviewed Original ResearchSmaller prostate volumeMulti-parametric MRISignificant prostate cancerProstate volumeProstate cancerROI ratioPSA densityGrade groupPrediction of csPCaRisk of csPCaData System (BI-RADS) category 3Prostate Imaging ReportingMpMRI findingsBiopsy databasePrior diagnosisTargeted biopsiesFusion biopsyPositive coresCsPCaUnnecessary biopsiesBiopsyMultivariate analysisPatientsImaging ReportingLesions
2017
Negative Multiparametric Magnetic Resonance Imaging of the Prostate Predicts Absence of Clinically Significant Prostate Cancer on 12-Core Template Prostate Biopsy
Lu AJ, Syed JS, Nguyen KA, Nawaf CB, Rosoff J, Spektor M, Levi A, Humphrey PA, Weinreb JC, Schulam PG, Sprenkle PC. Negative Multiparametric Magnetic Resonance Imaging of the Prostate Predicts Absence of Clinically Significant Prostate Cancer on 12-Core Template Prostate Biopsy. Urology 2017, 105: 118-122. PMID: 28322902, DOI: 10.1016/j.urology.2017.01.048.Peer-Reviewed Original ResearchConceptsMultiparametric magnetic resonance imagingSignificant prostate cancerProstate cancerNegative predictive valueMagnetic resonance imagingSystematic TRUSNegative mpMRIProstate biopsyNegative multiparametric magnetic resonance imagingPredictive valueResonance imagingClinically Significant Prostate CancerDynamic contrast enhancement sequencesTemplate mapping biopsyPrior negative biopsySystematic prostate biopsyOverall cancer detectionProstate-specific antigenTemplate prostate biopsyProstate cancer detectionDiffusion-weighted imagingCancer detectionBiopsy naïveMapping biopsyProstate volume
2016
MRI-US fusion targeted biopsy results in patients with a history of a prior negative biopsy.
Nawaf C, Lu A, Rosoff J, Weinreb J, Schulam P, Humphrey P, Levi A, Sprenkle P. MRI-US fusion targeted biopsy results in patients with a history of a prior negative biopsy. Journal Of Clinical Oncology 2016, 34: 90-90. DOI: 10.1200/jco.2016.34.2_suppl.90.Peer-Reviewed Original ResearchPrior negative biopsyCS cancerGleason scoreNegative MRIProstate cancerNegative biopsyCS prostate cancerMRI suspicion scoreMRI-US fusionPre-biopsy mpMRIFusion prostate biopsyMRI-ultrasound fusionSignificant prostate cancerCancer detection rateBiopsy of lesionsMaximum Gleason scoreMulti-parametric MRIElevated PSAPrevious biopsyRepeat biopsyMapping biopsyBiopsy resultsProstate biopsyFusion biopsyStandard biopsy
2015
Simplified prostate lesion grading for magnetic resonance imaging and improved cancer detection at fusion-targeted prostate biopsy.
Kardos S, Nawaf C, Fan R, Cornfeld D, Weinreb J, Schulam P, Sprenkle P. Simplified prostate lesion grading for magnetic resonance imaging and improved cancer detection at fusion-targeted prostate biopsy. Journal Of Clinical Oncology 2015, 33: 69-69. DOI: 10.1200/jco.2015.33.7_suppl.69.Peer-Reviewed Original ResearchCancer detection rateOverall cancer detection rateSignificant prostate cancerProstate cancerSystematic biopsyProstate biopsyFusion biopsyCommon solid organ malignancyEndorectal coilCores TRUS biopsyPrior negative biopsySolid organ malignanciesFusion prostate biopsyCochran-Armitage trend testCause of cancerMagnetic resonance imagingReal-time ultrasoundArmitage trend testAbnormal DRELesion stratificationElevated PSAOrgan malignanciesLesion gradingNegative biopsyTRUS biopsy